UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia

The oncologist (Dayton, Ohio), 2018-09, Vol.23 (9), p.1103-1108

2018

Volltextzugriff (PDF)

FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia

Clinical cancer research, 2018-07, Vol.24 (14), p.3242-3246

2018

Volltextzugriff (PDF)

FDA Approval: Blinatumomab

Clinical cancer research, 2015-09, Vol.21 (18), p.4035-4039

2015

Volltextzugriff (PDF)

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER‐2

The oncologist (Dayton, Ohio), 2008-10, Vol.13 (10), p.1114-1119

2008

Volltextzugriff (PDF)

Bayesian hierarchical methods for meta-analysis combining randomized-controlled and single-arm studies

Statistical methods in medical research, 2019-05, Vol.28 (5), p.1293-1310

2019

Volltextzugriff (PDF)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis

The oncologist (Dayton, Ohio), 2018-12, Vol.23 (12), p.1511-1519

2018

Volltextzugriff (PDF)

Bortezomib for the Treatment of Mantle Cell Lymphoma

Clinical cancer research, 2007-09, Vol.13 (18), p.5291-5294

2007

Volltextzugriff (PDF)

Racial disparities in stillbirth risk across gestation in the United States

American journal of obstetrics and gynecology, 2009-11, Vol.201 (5), p.469.e1-469.e8

2009

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia

The oncologist (Dayton, Ohio), 2014-01, Vol.19 (1), p.94-99

2014

Volltextzugriff (PDF)

Maternal age and the risk of stillbirth throughout pregnancy in the United States

American journal of obstetrics and gynecology, 2006-09, Vol.195 (3), p.764-770

2006

Volltextzugriff (PDF)

Delivery indications at late-preterm gestations and infant mortality rates in the United States

Pediatrics (Evanston), 2009-07, Vol.124 (1), p.234-240

2009

Volltextzugriff (PDF)

FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Clinical cancer research, 2017-11, Vol.23 (22), p.6759-6763

2017

Volltextzugriff (PDF)

U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia

Pediatric blood & cancer, 2017-12, Vol.64 (12), p.n/a

2017

Volltextzugriff (PDF)

Some Thoughts on the Use of Predictive Probability in Clinical Trials

Therapeutic innovation & regulatory science, 2023-05, Vol.57 (3), p.464-466

2023

Volltextzugriff (PDF)

Term pregnancy: a period of heterogeneous risk for infant mortality

Obstetrics and gynecology (New York. 1953), 2011-06, Vol.117 (6), p.1279-1287

2011

Volltextzugriff (PDF)

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease

Clinical cancer research, 2015-03, Vol.21 (5), p.950-954

2015

Volltextzugriff (PDF)

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses

Journal of clinical oncology, 2022-03, Vol.40 (8), p.847-854

2022

Volltextzugriff (PDF)

Factors associated with caregivers' choice of infant sleep position, 1994-1998: the National Infant Sleep Position Study

JAMA : the journal of the American Medical Association, 2000-04, Vol.283 (16), p.2135

2000

Volltextzugriff (PDF)

Toxicity of substituted anilines to Pseudokirchneriella subcapitata and quantitative structure-activity relationship analysis for polar narcotics

Environmental toxicology and chemistry, 2007-06, Vol.26 (6), p.1158-1164

2007

Volltextzugriff (PDF)

Low Serum Micronutrient Concentrations Predict Frailty Among Older Women Living in the Community

The journals of gerontology. Series A, Biological sciences and medical sciences, 2006-06, Vol.61 (6), p.594-599

2006

Volltextzugriff (PDF)

Americans hear as well or better today compared with 40 years ago: hearing threshold levels in the unscreened adult population of the United States, 1959-1962 and 1999-2004

Ear and hearing, 2010-12, Vol.31 (6), p.725-734

2010

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Clinical cancer research, 2014-08, Vol.20 (15), p.3902-3907

2014

Volltextzugriff (PDF)

Hearing threshold levels at age 70 years (65-74 years) in the unscreened older adult population of the United States, 1959-1962 and 1999-2006

Ear and hearing, 2012-05, Vol.33 (3), p.437-440

2012

Volltextzugriff (PDF)

Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1–34) Versus Calcitriol and Calcium

The journal of clinical endocrinology and metabolism, 2003-09, Vol.88 (9), p.4214-4220

2003

Volltextzugriff (PDF)

Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study

Therapeutic Innovation & Regulatory Science, 2013-01, Vol.47 (1), p.95-100

2013

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Aktive Filter

ThemaImmunology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(117)

Publikationsform

Sprache

Englisch
(136)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia

FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia

FDA Approval: Blinatumomab

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER‐2

Bayesian hierarchical methods for meta-analysis combining randomized-controlled and single-arm studies

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis

Bortezomib for the Treatment of Mantle Cell Lymphoma

Racial disparities in stillbirth risk across gestation in the United States

U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia

Maternal age and the risk of stillbirth throughout pregnancy in the United States

Delivery indications at late-preterm gestations and infant mortality rates in the United States

FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia

Some Thoughts on the Use of Predictive Probability in Clinical Trials

Term pregnancy: a period of heterogeneous risk for infant mortality

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses

Factors associated with caregivers' choice of infant sleep position, 1994-1998: the National Infant Sleep Position Study

Toxicity of substituted anilines to Pseudokirchneriella subcapitata and quantitative structure-activity relationship analysis for polar narcotics

Low Serum Micronutrient Concentrations Predict Frailty Among Older Women Living in the Community

Americans hear as well or better today compared with 40 years ago: hearing threshold levels in the unscreened adult population of the United States, 1959-1962 and 1999-2004

U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Hearing threshold levels at age 70 years (65-74 years) in the unscreened older adult population of the United States, 1959-1962 and 1999-2006

Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1–34) Versus Calcitriol and Calcium

Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study

Aktive Filter

Suchergebnisse filtern